Why Your Body Destroys NAD+ Before It Can Use It (And the $5 Fix Nobody Talks About)

Your body cannot use NAD+ directly. The molecule is too large to cross a cell membrane, so before any NAD+ you take or produce can actually do anything useful, it has to be broken down outside the cell, transported in as smaller pieces, and then reassembled inside through a process called the salvage pathway, which is essentially a recycling system that rebuilds NAD+ from its own breakdown products.

That is the map. Everything else in this article is about what happens inside that map and why one detail most people skip changes the whole picture.

The salvage pathway is where almost all NAD+ precursor supplements funnel. When you take NMN, something called CD73 converts it to NR, which is nicotinamide riboside, before it can even enter the cell. When you take NR directly, it enters as NR. Either way, both precursors end up at the same door. A 2016 study in Nature Communications confirmed this, showing that NMN has to be converted to NR by CD73 before cellular uptake, which means NMN and NR are not two different pathways. They are two different starting points on the same one-lane road.

That matters because the road gets more congested as you age.

There is an enzyme called CD38, which acts like a NAD+ shredder. Its job is to break NAD+ down, and it is not a minor player. A 2016 study in Cell Metabolism found that CD38 activity increases two to three fold across tissues as you age, and the correlation between CD38 activity and NAD+ levels runs almost perfectly in the opposite direction. More CD38 means less NAD+, and by the time you are middle-aged, your body is destroying NAD+ significantly faster than it did when you were young, regardless of how much you are feeding into the salvage pathway.

This is why the IV NAD+ argument, which you sometimes hear positioned as a way to bypass all of this, does not hold up the way its proponents suggest. A 2019 pilot study in Frontiers in Aging Neuroscience gave subjects 750 milligrams of NAD+ intravenously over six hours and tracked what happened. The NAD+ was completely removed from plasma before it ever reached cells. Every bit of it was degraded extracellularly into metabolites. The IV route does not bypass the problem. It just gets broken down in a different place.

So if the salvage pathway gets congested with age, and IV infusions do not circumvent that congestion, and both NMN and NR funnel through the same bottleneck, the obvious question is whether there is a different entrance entirely.

There is.

Your body has a second major pathway for building NAD+ called the Preiss-Handler pathway, and it does not share the same congestion point as the salvage pathway. The molecule that enters this pathway is niacin, which is just vitamin B3 in its oldest, least marketed form. Niacin converts to something called NAMN, which then proceeds through a completely separate enzymatic chain to produce NAD+.

A 2020 study in Cell Metabolism tested this directly in people with confirmed NAD+ deficiency caused by adult-onset mitochondrial myopathy. At doses of 750 to 1000 milligrams per day, niacin raised blood NAD+ levels 2.3 times and raised muscle NAD+ levels 1.3 times. Those subjects also showed improvements in muscle strength and markers of mitochondrial biogenesis. The effect was real, measurable, and produced by a molecule that costs roughly five dollars a month at any pharmacy.

For comparison, NMN and NR supplements typically run thirty to eighty dollars a month, and they funnel through the exact pathway that age-related CD38 accumulation is working against.

There is one thing worth adding here, because the research is not entirely clean on the separation between these two pathways. A 2019 study in Cell Reports found that when people supplemented with NR, they saw significant increases in something called NAAD, which is an intermediate in the Preiss-Handler pathway, inside muscle tissue. That suggests NR does not stay entirely within the salvage pathway. Some of it appears to convert to nicotinic acid in the body and then re-enter through the Preiss-Handler route. How much of NR's benefit comes from this cross-pathway conversion is not fully established yet, but it suggests the two systems are not as completely separate as the textbook diagrams make them look.

What is established is that niacin enters the Preiss-Handler pathway directly, without needing to make that conversion first, and the human data on its ability to raise NAD+ in people who are actually deficient is about as strong as anything in this space.

The practical takeaway is straightforward. Niacin does cause something called a flush, which is a temporary reddening and warming of the skin, for the first one to two weeks of use. This happens because niacin activates prostaglandin release, which dilates blood vessels near the skin. It is harmless and it fades as your body adapts. Extended-release niacin forms reduce the flush but have been associated with liver stress at high doses, so the immediate-release form is generally what the research uses and what makes more sense for this purpose.

Start low. Give the flush time to settle. The dose range in the study was 750 to 1000 milligrams, which is meaningfully higher than the standard dietary recommendation, so this is something to approach incrementally rather than jumping straight to the top of the range.

The deeper point here is not that NMN and NR are useless. It is that the mechanism your body uses to process them has a real, age-related limitation, and there is an alternate route that sidesteps that limitation entirely, and it has been sitting on pharmacy shelves for decades, largely ignored because it cannot be patented and sold at a premium.

The biology did not get more complicated. The marketing did.

---

References

1. Ratajczak J, Joffraud M, Trammell SAJ, et al. 2016. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7:13103. Finding: NMN must be converted to NR by CD73 before cellular uptake, establishing NR as the common entry point for both NMN and NR supplementation. Source
2. Elhassan YS, Kluckova K, Fletcher RS, et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 287:1717-1728. Finding: NR supplementation produced significant increases in NAAD a Preiss-Handler pathway intermediate in human muscle, indicating NR partially converts to nicotinic acid in vivo. Source
3. Pirinen E, Auranen M, Khan NA, et al. 2020. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 316:1078-1090. Finding: Niacin 750-1000 mg/day raised blood NAD+ 2.3x and muscle NAD+ 1.3x in human subjects via the Preiss-Handler pathway, with concurrent improvements in muscle strength and mitochondrial biogenesis. Source
4. Grant R, Berg J, Mestayer R, et al. 2019. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11:257. Finding: IV NAD+ 750 mg was rapidly and completely removed from plasma, with metabolites confirming full extracellular degradation before cellular uptake. Source
5. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. 2016. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 236:1127-1139. Finding: CD38 activity increases 2-3 fold with age across tissues, with near-perfect inverse correlation to NAD+ levels. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness